Global Oligonucleotide Synthesis Market Overview

Chem Reports estimates that the global Oligonucleotide Synthesis market was valued at USD xxxx in 2025 and is projected to reach USD xxxx by 2035, expanding at a CAGR of xx% during the forecast period. Market growth is driven by rapid advances in genomics, molecular diagnostics, and nucleic acid–based therapeutics, alongside increasing adoption of personalized medicine and precision diagnostics.

The Global Oligonucleotide Synthesis Market Report 2025 delivers a detailed evaluation of market size, growth drivers, technological evolution, and competitive dynamics. The report analyzes historical and current market trends to forecast demand from 2025 to 2035. The research is based on extensive primary and secondary data, encompassing regulatory frameworks, research funding trends, innovation in synthesis technologies, automation advancements, and expanding end-use applications across academic, pharmaceutical, and biotechnology sectors.

Impact of COVID-19 on the Oligonucleotide Synthesis Market

The COVID-19 pandemic had a net positive impact on the Oligonucleotide Synthesis market. While initial disruptions affected laboratory operations and supply chains in early 2020, demand rapidly increased due to large-scale testing, vaccine research, and diagnostic kit development. Oligonucleotides played a critical role in PCR-based diagnostics, accelerating market growth and highlighting the strategic importance of reliable synthesis capabilities. Post-pandemic, sustained investment in molecular diagnostics and infectious disease research continues to support market expansion.

Market Segmentation Analysis

By Type

Primer
Primers represent a major segment, driven by extensive use in PCR, qPCR, sequencing, and diagnostic applications. Growth is supported by rising demand for molecular diagnostics, genetic testing, and research workflows.

Probe
Probes are used in advanced diagnostic assays, gene expression analysis, and molecular imaging. Demand is increasing due to the growing adoption of real-time PCR and fluorescence-based detection techniques.

Reagent
This segment includes modified oligonucleotides, labeling reagents, and synthesis-related consumables. Growth is supported by continuous innovation in assay development and high-throughput research applications.

By Application

Academic
Academic and research institutions account for a significant share of demand, driven by genomics research, functional genomics studies, and government-funded life science programs.

Pharmaceutical
The pharmaceutical segment is experiencing strong growth due to increasing development of oligonucleotide-based therapeutics, including antisense oligonucleotides, siRNA, and mRNA-related research.

Biotechnology
Biotechnology companies utilize synthesized oligonucleotides in diagnostics, gene editing, synthetic biology, and therapeutic development, supporting consistent demand growth.

Competitive Landscape and Key Players Analysis

The Oligonucleotide Synthesis market is moderately consolidated, with global life science companies and specialized synthesis providers competing on quality, turnaround time, customization, and scalability. Key players invest heavily in automation, high-throughput synthesis platforms, and GMP-compliant manufacturing to support clinical and commercial applications.

Key Players Include:

• Integrated DNA Technologies, Inc.
• Merck KGaA
• Eurofins Genomics
• Thermo Fisher Scientific Inc.
• BioAutomation Corporation
• Agilent Technologies, Inc.
• Eurogentec S.A.
• General Electric (GE) Company
• LGC Biosearch Technologies, Inc.
• Nitto Denko Avecia Inc.

Leading companies differentiate through advanced synthesis technologies, global distribution networks, and strong relationships with pharmaceutical and biotechnology customers. Expansion of GMP manufacturing capacity and development of modified and therapeutic-grade oligonucleotides remain key competitive strategies.

Regional Analysis

North America
North America dominates the global market, driven by strong presence of pharmaceutical and biotechnology companies, advanced research infrastructure, and significant funding for genomics and molecular biology. The U.S. leads regional demand due to high adoption of nucleic acid–based diagnostics and therapeutics.

Europe
Europe represents a major market supported by well-established academic research institutions, growing biotechnology activity, and strong regulatory frameworks for molecular diagnostics and advanced therapies. Germany, the U.K., and France are key contributors.

Asia-Pacific
Asia-Pacific is the fastest-growing regional market, led by China, Japan, India, and Southeast Asia. Rising investments in biotechnology, expanding diagnostic testing capacity, and government initiatives to strengthen life sciences research drive regional growth.

South America
South America shows moderate growth potential, supported by expanding academic research activities, improving healthcare infrastructure, and gradual adoption of molecular diagnostics.

Middle East & Africa

The Middle East & Africa market is emerging, driven by increasing healthcare investments, growing diagnostic capabilities, and rising awareness of genomic technologies.

Executive Summary

The global Oligonucleotide Synthesis market is poised for robust growth through 2035, driven by rapid advancements in genomics, molecular diagnostics, and nucleic acid–based therapeutics. Oligonucleotides are foundational to PCR diagnostics, next-generation sequencing, gene editing, and emerging RNA-based drugs, positioning the market at the core of modern life sciences. Sustained investment in biotechnology, expanding clinical pipelines for antisense and RNA therapeutics, and increasing adoption of precision medicine are reinforcing long-term demand. While the market faces challenges related to cost, scalability, and regulatory compliance, technological innovation and capacity expansion continue to strengthen growth prospects.

Drivers, Restraints, Trends, and Opportunities (DRTO)

Drivers

• Expansion of Molecular Diagnostics and Genomics Research
  Increasing use of PCR, qPCR, and sequencing technologies in diagnostics and research is driving consistent demand for primers and probes.
• Growth of Oligonucleotide-based Therapeutics
  Rising clinical and commercial development of antisense oligonucleotides, siRNA, and RNA-based therapies significantly boosts synthesis demand.
• Increase in Biotechnology and Pharmaceutical R&D Spending
  Strong funding for life sciences research supports high-volume and customized oligonucleotide synthesis.
• Automation and High-throughput Synthesis Technologies
  Advances in synthesis platforms improve efficiency, accuracy, and scalability, enabling broader market adoption.

Restraints

• High Manufacturing and Purification Costs
  Advanced synthesis, modification, and purification processes increase production costs, especially for clinical-grade products.
• Regulatory and Quality Compliance Requirements
  GMP standards and regulatory approvals add complexity and cost for suppliers serving therapeutic applications.
• Technical Challenges in Large-scale Production
  Scaling oligonucleotide synthesis while maintaining quality and yield remains challenging.
• Dependency on Specialized Raw Materials
  Supply constraints for phosphoramidites and other key inputs can affect production timelines.

Trends

• Shift Toward Therapeutic-grade and GMP Manufacturing
  Increasing focus on clinical and commercial oligonucleotide production rather than research-only volumes.
• Rising Demand for Modified Oligonucleotides
  Chemical modifications to improve stability, delivery, and efficacy are becoming standard in therapeutic development.
• Integration of Automation and Digital Quality Control
  Manufacturers are adopting automated synthesis and real-time monitoring to improve consistency and reduce errors.
• Geographic Expansion of Manufacturing Capacity
  New facilities in Asia-Pacific and Europe aim to meet growing global demand and reduce supply chain risk.

Opportunities

• Growth in Personalized and Precision Medicine
  Customized oligonucleotides for targeted therapies and diagnostics offer significant expansion potential.
• Emerging Applications in Gene Editing and Synthetic Biology
  CRISPR, gene therapy, and synthetic biology research create new high-value demand streams.
• Outsourcing by Pharma and Biotech Companies
  Increasing reliance on specialized CDMOs for oligonucleotide synthesis supports service-based growth models.
• Expansion in Emerging Markets
  Growing research infrastructure and diagnostics adoption in Asia-Pacific and Latin America present long-term opportunities.

SWOT Analysis

Strengths

• Essential role in modern diagnostics and therapeutics
• High scientific and technological entry barriers
• Strong demand from pharma, biotech, and academic sectors
• Continuous innovation in synthesis and modification techniques

Weaknesses

• High cost of production and purification
• Complex regulatory and quality requirements
• Dependence on specialized raw materials and equipment
• Limited number of large-scale GMP manufacturers

Opportunities

• Rapid growth of RNA-based drugs and gene therapies
• Increasing outsourcing of synthesis services
• Expansion of high-throughput and automated platforms
• Rising adoption of molecular diagnostics globally

Threats

• Pricing pressure from increased competition
• Regulatory delays affecting therapeutic programs
• Technological obsolescence due to rapid innovation
• Supply chain disruptions for critical synthesis inputs

Porter’s Five Forces Analysis

Threat of New Entrants – Low to Moderate

High capital investment, technical expertise, and regulatory compliance requirements limit new market entry.

Bargaining Power of Suppliers – Moderate

Suppliers of specialized reagents exert moderate power due to limited availability, though long-term contracts mitigate risk.

Bargaining Power of Buyers – High

Pharmaceutical and biotechnology companies possess strong negotiating leverage due to large-volume contracts and multiple supplier options.

Threat of Substitutes – Low

There are limited substitutes for synthetic oligonucleotides in diagnostics and therapeutic development.

Competitive Rivalry – High

The market is highly competitive, with leading players competing on quality, turnaround time, customization, and regulatory capabilities.

Competitive Landscape Matrix

The Middle East & Africa market is emerging, driven by increasing healthcare investments, growing diagnostic capabilities, and rising awareness of genomic technologies.